The stock option award to Dr. Jorgensen provides for the purchase of an aggregate of 200,000 shares of Voyager's common stock, and the restricted stock unit award to Dr. Jorgensen will represent 80,000 shares of Voyager's common stock. The stock option has a ten-year term and an exercise price of $7.79 per share, which is equal to the closing price of Voyager's common stock on July 8, 2024, the effective date of grant. The stock option vests over four years, with 25% of the shares underlying the stock optio ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer Alfred Sandrock - CEO Todd Carter - Chief Scientific Officer Toby Ferguson - Chief Medical Officer Robin Swartz - COO and Principal Financial Officer Conference Call Participants Mehdi Goudarzi - Truist Securities Jack Allen - Baird Patrick Trucchio - H.C. Wainwright & Co. Philip Nadeau - TD Cowen Ry Forseth - Guggenheim Securities David Hoa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-30031 ...

EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer's disease; expect to begin single ascending dose trial in the coming weeks – – Development candidates selected for Neurocrine-partnered GBA1 and Friedreich's Ataxia gene therapy programs; potential for three gene therapies, including SOD1- ALS, to enter the clinic in 2025 – – Appointed neurology cl ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Results Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Peter Pfreundschuh - Chief Financial Officer Alfred Sandrock - President and Chief Executive Officer Todd Carter - Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird Sam Beck - Citigroup Jay Olson - Oppenheimer & Co. Ry Forseth - Guggenheim Securities Phil Nadeau - TD Cowen Mehdi Goudarzi - Truist Securities Sumant Kulkarni - Canaccord Genuity In ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-3003182 (State o ...

– Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering – – Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially enabling the generation of clinical data from multiple programs – EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Key Milestones Achieved in Q4 2023 and Subsequent P ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Results Conference Call November 6, 2023 4:30 PM ET Company Participants Pete Pfreundschuh - CFO Dr. Al Sandrock - CEO Dr. Todd Carter - Chief Scientific Officer Conference Call Participants Joon Lee - Truist Securities Jack Allen - Baird Jay Olson - Oppenheimer Laura Chico - Wedbush Yanan Zhu - Wells Fargo Sumant Kulkarni - Canaccord Divya Rao - TD Cowen Operator Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2023 Conference Call. All ...

Gene Therapy Development - The company has developed a proprietary AAV capsid discovery platform called TRACERTM, which enhances tissue delivery characteristics and aims to improve gene therapy efficacy and safety [145]. - The company has identified a lead development candidate for its anti-tau antibody program and expects to submit an IND application to the FDA in the first half of 2024 [148]. - The company anticipates submitting the IND for its SOD1 gene therapy program in mid-2025, with a lead development candidate expected to be identified in 2023 [148]. - The company presented data showing greater than 50% cell transduction in multiple areas of the brain at a dose of 2x10^12 vector genomes per kilogram using its VCAP-102 TRACER Capsid in marmosets [158]. - The company is advancing two later preclinical stage programs in collaboration with Neurocrine for Parkinson's disease and Friedreich's ataxia [148]. - The company is developing gene therapy products for Parkinson's disease and Friedreich's ataxia, currently in preclinical development [190][197]. - The company plans to complete IND enabling studies to evaluate the safety and efficacy of lead candidates for its gene therapy programs [190][197]. - The company is exploring a gene therapy targeting tau and anti-amyloid for Alzheimer's disease, with early research initiatives announced in 2023 [177][178]. - The GBA1 gene therapy for Parkinson's disease targets a population of about 1 million patients in the U.S. and over 10 million worldwide, with GBA1 mutations increasing the risk of Parkinson's disease by approximately 20-fold [187]. - The company presented preclinical data showing significant improvements in efficacy biomarkers for the GBA1 gene therapy at the ASGCT 2023 Meeting [189]. Collaboration Agreements and Financials - Under the 2019 Neurocrine Collaboration Agreement, the company received an upfront payment of $115 million and an equity purchase of $50 million for 4,179,728 shares of common stock [160]. - The company is eligible for aggregate development milestone payments of up to $195 million for the FA Program and up to $130 million for each of the two 2019 Discovery Programs [160]. - The company may receive aggregate commercial milestone payments of up to $275 million, subject to a cap of $1.1 billion across all 2019 Neurocrine Programs [160]. - The 2023 Neurocrine Collaboration Agreement includes potential development milestone payments of up to $985.0 million for the GBA1 Program and up to $175.0 million for each of the three 2023 Discovery Programs [164]. - Under the Alexion Agreement, Pfizer paid an upfront payment of $30 million and an additional $10 million related to the exercise of the Pfizer License Option for a rare neurological disease [168]. - The company is eligible for up to $115 million in specified milestone payments for the first Alexion Licensed CNS Product and up to $175 million in sales milestone payments per product [168]. - As of September 30, 2023, the company had an accumulated deficit of $317.6 million [198]. - For the three months ended September 30, 2023, collaboration revenue was $4.6 million, a decrease of $36.5 million compared to $41.1 million in the same period in 2022 [214]. - The company recognized $79.0 million of collaboration revenue from the Novartis Agreement for the nine months ended September 30, 2023 [201]. - Collaboration revenue increased significantly to $159.9 million for the nine months ended September 30, 2023, compared to $42.5 million for the same period in 2022, reflecting a change of $117.5 million [220]. Expenses and Financial Performance - Research and development expenses increased by $6.5 million to $25.9 million for the three months ended September 30, 2023, compared to $19.3 million in the same period in 2022 [215]. - Research and development expenses rose to $66.4 million for the nine months ended September 30, 2023, up from $46.2 million in 2022, marking an increase of $20.2 million [221]. - General and administrative expenses increased to $25.6 million for the nine months ended September 30, 2023, compared to $22.5 million in 2022, an increase of $3.1 million [222]. - Interest income surged to $8.6 million for the nine months ended September 30, 2023, compared to $0.8 million in 2022, reflecting an increase of $7.8 million [223]. - Net income before income taxes improved to $76.5 million for the nine months ended September 30, 2023, compared to a net loss of $22.8 million in 2022, a positive change of $99.3 million [219]. - The company expects to continue incurring significant expenses and operating losses for the foreseeable future due to ongoing development activities [198]. - The company anticipates that its expenses will increase substantially as it conducts preclinical development activities and initiates clinical trials [198]. - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future [201]. Cash Flow and Financial Position - Cash, cash equivalents, and marketable securities totaled $252.9 million as of September 30, 2023, supporting operations into mid-2025 [225]. - Net cash provided by operating activities was $101.7 million for the nine months ended September 30, 2023, compared to a net cash used of $0.3 million in 2022 [227]. - Net cash used in investing activities increased to $168.5 million for the nine months ended September 30, 2023, from $21.4 million in 2022, primarily due to increased purchases of marketable securities [228]. - The company anticipates continued increases in expenses related to research and development and operational costs due to inflation and ongoing development programs [230]. - Future capital requirements will depend on various factors, including the success of product candidates and the ability to secure additional financing [233]. Risk Factors - The company has agreements to license intellectual property that include potential milestone payments contingent upon clinical trial or regulatory approval milestones [238]. - Annual maintenance fees or minimum amounts payable under these agreements range from low-four digits to low five-digits [238]. - The company has non-cancelable operating lease commitments for office and laboratory space in Cambridge and Lexington, Massachusetts [239]. - The company is primarily exposed to interest rate sensitivity, with an immediate 100 basis point change in interest rates not materially affecting the fair market value of its investment portfolio [242]. - There is currently no exposure to market risk related to foreign currency exchange rates, but future contracts with vendors in Asia and Europe may introduce such risks [243]. - Inflation has not had a material effect on the company's business, financial condition, or results of operations during the nine months ended September 30, 2023 [244].

Start Time: 08:30 January 1, 0000 9:08 AM ET Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2023 Earnings Conference Call August 03, 2023, 08:30 AM ET Company Participants Al Sandrock - President and CEO Pete Pfreundschuh - CFO Todd Carter - Chief Scientific Officer Conference Call Participants Joon Lee - Truist Securities Ingrid Ibarra - Wedbush Jack Allen - Baird Philip Nadeau - TD Cowen Matthew Hershenhorn - Oppenheimer Ross Fladeland - Canaccord Genuity Operator Good morning and welcome to Voyager Therapeu ...